Bayer CropScience Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Simon-Thorsten Wiebusch
Algemeen directeur
₹87.5m
Totale compensatie
| Percentage CEO-salaris | 82.06% |
| Dienstverband CEO | 2.5yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.1yrs |
| Gemiddelde ambtstermijn bestuur | 1.8yrs |
Recente managementupdates
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₹7b |
| Sep 30 2025 | n/a | n/a | ₹6b |
| Jun 30 2025 | n/a | n/a | ₹6b |
| Mar 31 2025 | ₹87m | ₹72m | ₹6b |
| Dec 31 2024 | n/a | n/a | ₹5b |
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹7b |
| Mar 31 2024 | ₹86m | ₹70m | ₹7b |
| Dec 31 2023 | n/a | n/a | ₹8b |
| Sep 30 2023 | n/a | n/a | ₹8b |
| Jun 30 2023 | n/a | n/a | ₹8b |
| Mar 31 2023 | ₹96m | ₹82m | ₹8b |
| Dec 31 2022 | n/a | n/a | ₹8b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹29m | ₹25m | ₹6b |
Compensatie versus markt: De totale vergoeding ($USD 903.57K ) Simon-Thorsten } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 465.13K ).
Compensatie versus inkomsten: De vergoeding van Simon-Thorsten is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Simon-Thorsten Wiebusch (49 yo)
Mr. Simon-Thorsten Wiebusch is Vice Chairman, Managing Director and Chief Executive Officer of Bayer CropScience Limited from November 1, 2023. Mr. Wiebusch was Whole-Time Director at Bayer CropScience Lim...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Vice Chairman | 2.5yrs | ₹87.47m | geen gegevens | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | geen gegevens | |
| Company Secretary & Compliance Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Country Division Head of the Pharmaceutical Division | 2.3yrs | geen gegevens | geen gegevens | |
| Country Group Mngr of Environmental Science for India | no data | ₹2.36m | geen gegevens |
Ervaren management: Het managementteam van 506285 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Vice Chairman | 4.4yrs | ₹87.47m | geen gegevens | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | geen gegevens | |
| Non-Executive Independent Chairman | 9.8yrs | ₹2.06m | geen gegevens | |
| Non-Executive Woman Independent Director | 1.8yrs | ₹660.00k | geen gegevens | |
| Additional Non-Executive Independent Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Non-Independent Director | 6.7yrs | geen gegevens | geen gegevens | |
| Non-Executive Non-Independent Director | 1.2yrs | geen gegevens | geen gegevens |
Ervaren bestuur: De raad van bestuur van 506285 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 05:15 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bayer CropScience Limited wordt gevolgd door 26 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |